At the news
? BEARISHIMPACT 7/10 S-4 filed Sep 1, 2026 at 21:42 ET
Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-held Slate Medicines. Under the agreement, pre-merger Slate stockholders (excluding concurrent investors) will own ~55.9% of the combined company, new investors in a concurrent $245M investment will own ~39.1%, and pre-merger Fulcrum stockholders will own only ~5.0% on a fully diluted basis. Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270M, but their equity stake in the combined entity is minimal, making this effectively a sale of Fulcrum's public shell and net cash to Slate.
- Pre-merger Fulcrum stockholders will own only ~5.0% of the combined company on a fully diluted basis.
- Pre-merger Slate stockholders (excluding investors) will own ~55.9%, and new investors in a $245M concurrent investment will own ~39.1%.
- Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270 million.
- Fulcrum's valuation is assumed at $31.3M, subject to downward adjustment if net cash at closing is less than $20.3M.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access